The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey

Am J Gastroenterol. 2007 Sep;102(9):1920-30. doi: 10.1111/j.1572-0241.2007.01370.x. Epub 2007 Jun 15.

Abstract

Objective: Liver cirrhosis is a major component in staging for hepatocellular carcinoma (HCC). The model for end-stage liver disease (MELD) is a better prognostic predictor for cirrhotic patients compared to the Child-Turcotte-Pugh (CTP) system, which is a parameter in Cancer of Liver Italian Program (CLIP), Barcelona Clinic Liver Cancer (BCLC), and Japan Integrated Scoring (JIS) system.

Aim: To investigate if the MELD-based models have a better prognostic ability.

Methods: In the MELD-based model, the CTP class was replaced with MELD score at cutoffs of <10, 10-14, and >14. The modified systems were prospectively compared with the original counterpart in 430 consecutive HCC patients. Using 6-month mortality as the end point, the area under receiver operating characteristic curve (AUC) between the original and modified system was compared sequentially on a 3-monthly basis.

Results: At the final inspection, the modified CLIP and JIS system had a significantly higher AUC compared to the original system (0.92 vs 0.893 for CLIP, P < 0.018; 0.88 vs 0.842 for JIS, P= 0.002), but there was no significant difference for the BCLC system (0.848 vs 0.841, P= 0.561). Survival analysis showed modified CLIP and JIS, and to a lesser extent, modified BCLC system, had a higher homogeneity likelihood ratio and discriminatory ability linear trend, and a lower Akaike information criterion in the Cox multivariate model, indicating a better discriminatory ability for different stage categories.

Conclusions: The MELD-based CLIP and JIS staging systems have an improved predictive ability compared to the original system and are feasible models for HCC staging in the MELD era.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Area Under Curve
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / mortality*
  • Female
  • Humans
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / pathology
  • Liver Neoplasms / complications
  • Liver Neoplasms / mortality*
  • Male
  • Models, Statistical*
  • Neoplasm Staging
  • Prognosis
  • ROC Curve
  • Sensitivity and Specificity
  • Survival Analysis
  • Survival Rate